Page 17 of 21
Journal of the American Chemical Society
1
2
3
4
5
6
7
8
9
(3) For modest, positive effects, see: (a) Le Bars, P. L.; Katz
(7) NTP Technical Report on the Toxicology and carcino-
genesis studies of Ginkgo bilobaextract (CAS No. 90045-36-6) in
F344/N rats and B6C3F1/N mice (Gavage studies). Natl. Toxicol.
Program Tech. Rep. Ser. 2013, 578, 1.
(8) Fernandez, F.; Morishida, W.; Zuniga, E.; Nguyen, J.;
Blank, M.; Malenka, R. C.; Garner, C. C. Pharmacotherapy for
cognitive impairment in a mouse model of Down syndrome. Na-
ture Neurosci. 2007, 10, 411.
(9) Kiewert, C.; Kumar, V.; Hildmann, O.; Rueda, M.; Hart-
mann, J.; Naik, R. S.; Klein, J. Role of GABAergic antagonism in
the neuroprotective effects of bilobalide. Brain Res. 2007, 1128,
70.
(10) Masiulis, S. Desai, R.; Uchanski, T.; Martin, I. S.;
Laverty, D.; Malinauskas, T.; Zivanov, J.; Pardon, E.; Kotecha,
A.; Steyaert, J.; Miller, K. W.; Aricescu, A. R. GABAA receptor
signaling mechanisms revealed by structural pharmacology. Na-
ture 2019, 565, 454.
(11) (a) Atzori, C.; Bruno, A.; Chichino, G.; Bombardelli, E.;
Scaglia, M.; Ghione, M. Activity of Bilobalide, a Sesquiterpene
from Ginkgo biloba, on Pneumocystis carinii. Antimicrob. Agents
Chemother. 1993, 37, 7, 1492; (b) Bombardelli, E.; Ghione, M.
Pharmaceutical Uses of Bilobalide and Derivatives Thereof and
Pharmaceutical Compositions Adapted for Such Use. U.S. Pat.
Appl. US005264216A, 1993; (c) Bombardelli, E.; Ghione, M.
Bilobalide Derivatives, Their Applications and Formulations Con-
taining Them. US005202313A, 1993; (d) Bombardelli, E.;
Ghione, M. Use of bilobalide and derivatives thereof for treating
an infection in an individual and pharmaceutical compositions
adapted for such use. EP0556051B1, 1997.
(12) (a) Pan, L.; Ren, L.; Chen, F.; Feng, Y.; Luo, Y. Anti-
feedant Activity of Ginkgo biloba Secondary Metabolites against
Hyphantria cunea Larvae: Mechanisms and Applications. PLoS
ONE 2016, 11, 1; (b) Pszczolkowski, M. A.; Durden, K.; Sellars,
S.; Cowell, B.; Brown, J. J. Effects of Ginkgo biloba Constituents
on Fruit-Infesting Behavior of Coding Moth (Cydia pomonella) in
Apples. J. Agric. Food Chem. 2011, 59, 10879-10886. (c) Ahn,
Y. J.; Kwon, M.; Park, H. M., Han, C. K. Potent Insecdticidal
Activity of Ginkgo biloba Derived Trilactone Terpenes. ACS
Symposium Series 1997, Ch. 7, 90; (d) Ozoe, Y. γ-aminobutyrate-
and glutamate-gated chloride channels as targets of insecticides.
Advances in Insect Physiology, 2013, 44, 211.
(13) Major, R. T. The Ginkgo, the most ancient living tree,
Science 1967, 157, 1270.
(14) Koch, E. Inhibition of platelet activating factor (PAF)-
induced aggregation of human thrombocytes by ginkgolides: con-
siderations on possible bleeding complications after oral intake of
Ginkgo biloba extracts. Phytomedicine 2005, 12, 10.
(15) Lee, D.; Su, H.; O’Dowed, D. K. GABA receptors Con-
taining Rdl Subunits Mediate Fast Inhibitory Synaptic Transmis-
sion in Drosophola Neurons. J. Neuroscience 2003, 23, 4625.
(16) (a) Constant, R. H. F.; Steichen, J. C.; Rocheleau, T. A.;
Aronstein, K.; Roush, R. T. A single-amino acid substitution in a
γ-aminobutyric acid subtype A receptor locus is associated with
cyclodiene insecticide resistance in Drosophila populations.
PNAS, 1993, 90, 1957; (b) Thompson, A. J.; McGonigle, I.; Duke,
R.; Johnston, G. A. R.; Lummis, S. C. R. A single amino acid
determines the toxicity of Ginkgo biloba extracts. FASEB J. 2012,
26, 1884.
M. M.; Bermann N.; Itil, T. M.; Freedman, A. M; Schatzberg, A.
F. A placebo-controlled, double-blind, randomized trial of an
extract of Ginkgo biloba for dementia, North American EGb
Study Group. JAMA 1997, 278, 1327; (b) Herrschaft, H.; Nacu,
A.; Likhachev, S.; Sholomov, I.; Hoerr, R.; Schlaefke, S. Ginkgo
biloba extract EGb 761® in dementia with neuropsychiatric fea-
tures: a randomised, placebo-controlled trial to confirm the effica-
cy and safety of a daily dose of 240 mg. J. Psychiatr. Res. 2012,
46, 716; (c) Tan, M. S.; Yu, J. T.; Tan, C. C.; Wang, H. F.; Meng,
X. F.; Wang, C.; Jiang, T.; Zhu, X.C.; Tan, L. Efficacy and ad-
verse effects of ginkgo biloba for cognitive impairment and de-
mentia: a systematic review and meta-analysis. J. Alzheimers Dis.
2015, 43, 589; (d) Yuan, Q.; Wang, C.W.; Shi, J.; Lin, Z. X. Ef-
fects of Ginkgo biloba on dementia: An overview of systematic
reviews. J. Ethnopharmacol. 2017, 195, 1. For no effect, see: (e)
Schneider, L.S.; DeKosky, S.T.; Farlow, M.R.; Tariot. P.N.; Ho-
err, R.; Kieser, M. A randomized, double-blind, placebo-
controlled trial of two doses of Ginkgo biloba extract in dementia
of the Alzheimer's type. Curr Alzheimer Res. 2005, 5, 541; (f)
Butler, M.; Nelson, V. A.; Davila, H.; Ratner, E.; Fink, H. A.;
Hemmy, L. S.; McCarten, J. R.; Barclay, T. R.; Brasure, M.;
Kane, R. L. Over-the-Counter Supplement Interventions to Pre-
vent Cognitive Decline, Mild Cognitive Impairment, and Clinical
Alzheimer-Type Dementia: A Systematic Review. Ann. Intern.
Med. 2018, 168, 52; (g) DeKosky, S. T.; Williamson, J. D.; Fitz-
patrick, A. L.; Kronmal, R. A.; Ives, D. G.; Saxton, J. A.; Lopez,
O. L.; Burke, G.; Carlson, M. C.; Fried, L. P.; Kuller, L. H.; Rob-
bins, J. A.; Tracy, R. P.; Woolard, N. F.; Dunn, L.; Snitz, B. E.;
Nahin, R. L.; Furberg, C. D. Ginkgo Evaluation of Memory
(GEM) Study Investigators, Ginkgo biloba for prevention of de-
mentia: a randomized controlled trial. JAMA 2008, 300, 2253; (h)
Vellas, B.; Coley, N.; Ousset, P. J.; Berrut, G.; Dartigues, J. F.;
Dubois, B.; Grandjean, H.; Pasquier, F.; Piette, F.; Robert, P.;
Touchon, J.; Garnier, Mathiex-Fortunet, H.; Andrieu, S.; GuidAge
Study Group. Long-term use of standardised Ginkgo biloba ex-
tract for the prevention of Alzheimer's disease (GuidAge): a ran-
domised placebo-controlled trial. Lancet Neurol. 2012, 10, 851;
(i) Charemboon, T.; Jaisin, K. Ginkgo biloba for prevention of
dementia: a systematic review and meta-analysis. J. Med. Assoc.
Thai. 2015, 5, 508; (j) Laws, K. R.; Sweetnam, H.; Kondel, T. K.
Is Ginkgo biloba a cognitive enhancer in healthy individuals? A
meta-analysis. Hum Psychopharmacol. 2012, 6, 527; (k) For a
summary, see: Nguyen, T.; Alzahrani, T. Ginkgo Biloba. [Updat-
ed 2019 Oct 3]. In: StatPearls [Internet]. Treasure Island (FL):
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
StatPearls
Publishing;
2019
Jan-. Available
from:
(4) Mei, N.; Guo, X.; Ren, Z.; Kobayashi, D.; Wada, K.;
Guo, L. Review of Ginkgo biloba-induced toxicity, from experi-
mental studies to human case reports. J. Environ. Sci. Health Part
C 2017, 35, 1.
(5) Clarke, T. C.; Black, L. I.; Stussman, B. J.; Barnes, P. M.;
Nahin, R. L. Trends in the use of complementary health ap-
proaches among adults: United States, 2002–2012. National
health statistics reports 2015, no. 79. Hyattsville, MD: National
Center for Health Statistics.
(6) Madgula V. L.; Avula, B.; Yu, Y. B.; Wang, Y. H.;
Tchantchou, F.; Fisher, S.; Luo, Y.; Khan, I. A.; Khan, S. I. Intes-
tinal and blood-brain barrier permeability of ginkgolides and bi-
lobalide: in vitro and in vivo approaches. Planta Med. 2010, 76,
599.
(17) (a) Huang, S. H., Duke, R. K., Chebib, M., Sasaki, K.,
Wada, K., and Johnston, G. A. Bilobalide, a sesquiterpene tri-
lactone from Ginkgo biloba, is an antagonist at recombinant
17
ACS Paragon Plus Environment